Eiger BioPharmaceuticals is a clinical stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of orphan diseases. The Company's resulting pipeline includes several Phase 2 development programs addressing four distinct orphan diseases. The pipeline includes lonafarnib for Hepatitis Delta Virus, or HDV, PEG-interferon lambda-1a (lambda) for HDV, exendin 9-39 for Post-Bariatric Hypoglycemia, or PBH and ubenimex for Pulmonary Arterial Hypertension, or PAH and lymphedema.